Positive data for Port Delivery System with ranibizumab (PDS) from the Phase III Archway study in patients with neovascular age-related macular degeneration

Data from the study show ranibizumab PDS (refilled every 6 months) was equivalent to ranibizumab 0.5mg monthly injections (average gain 0.2 v 0.5 eye chart letters, respectively, from baseline to week 40), with 98.4% of PDS patients maintaining the fixed 6-month refill schedule.

SPS commentary:

PDS is a permanent refillable eye implant, approximately the size of a grain of rice. It continuously delivers a customised formulation of ranibizumab over a period of months. Results from the Archway study, which included people who had received prior treatment with anti-VEGF therapy and were known responders, are due for presentation on July 26th 2020 at the Annual Meeting of the American Society of Retina Specialists.


Biospace Inc.